Belite Bio - American Depositary Shares (BLTE) closed at $150.27 on October 22, 2026, down 1.9% from the previous close, on volume of 100,339 shares (30-day average 162,516).
Data as of October 22, 2026.
Belite Bio moves up to Nasdaq’s top tier as it targets a potential first-ever Stargardt therapy
Market Chameleon (Tue, 20-Oct 7:59 AM ET)
Belite Bio Uplists to Nasdaq Global Select Market as Retinal Drug Program Advances
TipRanks (Mon, 19-Oct 6:27 AM ET)
Belite Bio to uplist to Nasdaq Global Select Market
Seeking Alpha News (Mon, 19-Oct 6:22 AM ET)
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Globe Newswire (Mon, 19-Oct 6:00 AM ET)
Globe Newswire (Wed, 14-Oct 4:00 PM ET)
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Globe Newswire (Mon, 28-Sep 8:00 PM ET)
Globe Newswire (Tue, 8-Sep 6:00 AM ET)
Belite Bio to Participate in Four Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Belite Bio to Host Virtual Commercial Day on September 2, 2026
Globe Newswire (Mon, 24-Aug 4:00 PM ET)
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
Globe Newswire (Wed, 12-Aug 9:45 PM ET)
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Belite Bio - American Depositary Shares trades on the NASDAQ stock market under the symbol BLTE.
As of October 22, 2026, BLTE stock price declined to $150.27 with 100,339 million shares trading.
BLTE has a beta of 1.07, meaning it tends to be more sensitive to market movements. BLTE has a correlation of 0.07 to the broad based SPY ETF.
BLTE has a market cap of $5.64 billion. This is considered a Mid Cap stock.
In the last 3 years, BLTE traded as high as $200.00 and as low as $31.01.
The top ETF exchange traded funds that BLTE belongs to (by Net Assets): SPEM, APIE, ONEQ, GXC, BBC.
BLTE has outperformed the market in the last year with a return of +63.3%, while the SPY ETF gained +14.9%. However, in the most recent history, BLTE shares have underperformed the stock market with its stock returning -6.7% in the last 3 month period and -3.7% for the last 2 week period, while SPY has returned +2.3% and -1.7%, respectively.
BLTE support price is $148.88 and resistance is $157.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLTE shares will trade within this expected range on the day.
